Company launched to advance women's health drug

KaNDy Therapeutics was launched on Wednesday to take forward NT-814, a potential breakthrough medicine for chronic debilitating women’s health conditions, with backing from investors including Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed Advisors.

The drug is a once daily, dual mechanism neurokinin-1,3 receptor antagonist being developed as a non-hormonal alternative for postmenopausal vasomotor symptoms (PMVMS). NT-814 has been spun out of NeRRe Therapeutics Holdings into KaNDy Therapeutics, a separate legal entity.

The UK-based company will advance NT-814 into Phase IIb in the lead indication of PMVMS while also exploring its potential in other women's health conditions.